The NO-sGC-cGMP pathway is an established target for cardiovascular drugs (e.g., nitroglycerin for angina and acute heart failure, sodium nitroprusside for hypertension, isosorbide mononitrate for chronic heart failure, phosphodiesterase 5[PDE5] inhibitors for pulmonary arterial hypertension) and non-cardiovascular drugs (e.g., PDE5 inhibitors for erectile dysfunction and benign prostatic hyperplasia). This evidence concerns the gene PDE5A and benign prostatic hyperplasia.